Cognition Therapeutics, Inc. reported that its Phase 2 MAGNIFY study of oral zervimesine (CT1812) in geographic atrophy (dry AMD) successfully passed a pre-defined futility analysis. The masked analysis showed that participants receiving zervimesine for at least six months experienced slower lesion growth compared to those on placebo.
Despite these positive efficacy signals, management made a strategic decision to conclude the Phase 2 study. This decision was taken to preserve capital and reallocate resources to the company's ongoing and promising programs in Alzheimer’s disease and dementia with Lewy bodies.
The early conclusion of the MAGNIFY study was not due to any safety concerns. A full analysis of the data from this study is expected to be provided in the second quarter of 2025, offering further insights into zervimesine's potential in dry AMD despite the strategic shift.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.